NCT06003231 2026-03-16
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT07285941 2025-12-16
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06063018 2023-10-02
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting